Thank you for registering your account
Thanks for joining touchONCOLOGY to hear about news and updates from across the Oncology community.
We’ve sent you an email to verify your email address. Please click on the link to confirm your account.
You can review your email preferences at any time or update your account details
Targeting IL-1β in NSCLC: What does the future hold?
Watch a panel of experts discuss immunotherapy for non-small cell lung cancer (NSCLC) and the possible future role of interleukin-1β (IL-1β) blockade.
- Discuss the use of checkpoint inhibitors as immunotherapy for NSCLC and recognize their limitations
- Recall the rationale for targeting IL-1β in cancer immunotherapy and the IL-1β-targeted agents currently in clinical development for solid tumours
- Describe the clinical trials and data for IL-1β-targeting agents in NSCLC and consider how they may be used in clinical practice if approved
A moving target: Assessing the role of EGFR-TKIs in early-stage NSCLC
Dr Stephen Liu presents the latest data and future directions of targeted therapy within the rapidly evolving treatment landscape for patients with early-stage NSCLC.
- Recall the latest efficacy and safety data for EGFR-TKIs for patients with early-stage EGFR-mutant NSCLC
- Describe how the evolving use of EGFR-TKIs may impact the current recommendations for mutation testing in NSCLC
- Discuss how EGFR-TKIs may be incorporated into the evolving treatment pathway for early-stage NSCLC, now and in the future
What is the current state of play of CAR T-cell therapy for B-cell malignancies? Focus on patient selection, safety and new indications
Learn about patient selection for chimeric antigen receptor (CAR) T-cell therapy, adverse event management and the latest developments in CAR T-cell therapies for B-cell malignancies from experts in the field.
- Describe patients who may be eligible for treatment with CAR T-cell therapy
- Review the management of adverse events associated with CAR T-cell therapy
- Discuss how CAR T-cell therapy might impact the treatment pathway for new indications
Alison Birtle, ASCO GU 2021: Peri-operative Chemotherapy versus Surveillance in Upper Tract Urothelial Cancer
touchONCOLOGY joins Dr Alison Birtle (Consultant Oncologist and Honorary Senior Lecturer, Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK) to discuss the updated primary and secondary analysis of the POUT trial in upper tract urothelial cancer (ClinicalTrials.gov Identifier: NCT01993979). The abstract “Updated outcomes of POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance […]
Jean-Luc Van Laethem, ASCO GI 2021: Results of the KEYNOTE-224 Study
We were delighted to talk to Jean-Luc Van Laethem (Hôpital Universitaire Erasme, Université Libre de Bruxelles, Brussels, Belgium) about the efficacy and safety findings of the KEYNOTE-224 study (Clinical Trial Identifier: NCT02702414). The abstract ‘Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study’ (ABSTRACT NUMBER: 297) was presented at the […]
Sara Tolaney, St. Gallen Breast Cancer Conference 2021: Patient-reported outcomes from MonarchE
Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) joins touchONCOLOGY to discuss the patient-reported health-related quality-of-life outcomes data from the MonarchE trial (ClinicalTrials.gov Identifier: NCT03155997) in patients with HR+, HER2- breast cancer being treated with abemaciclib plus endocrine therapy. The e-poster ‘Patients’ quality of life and side effect perceptions in monarchE, […]
Axel Merseburger, ASCO GU 2021: Apalutamide in Metastatic Castration-sensitive Prostate Cancer
We were delighted to talk to Editor-in-Chief Prof. Axel Merseburger (Professor and Chairman, Department of Urology, University of Lübeck, Lübeck, Germany) around the TITAN trial in metastatic castration-sensitive prostate cancer (ClinicalTrials.gov Identifer: NCT02489318). The abstract “Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic […]
Nivolumab for the Treatment of Esophageal Squamous Cell Carcinoma
Oncology & Hematology Review. 2020;16(2):90–4 DOI: https://doi.org/10.17925/OHR.2021.16.2.90
Esophageal cancer is the seventh most common malignancy and the sixth leading cause of death from cancer worldwide.1 The main histological subtypes are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma. ESCC is the most common subtype, and the frequency of this disease is highest in Eastern Asia and Eastern Africa.2 In Western countries, however, the incidence […]
Latest Developments in Cellular Therapy for Multiple Myeloma
Oncology & Hematology Review (US). 2020;16(2):111-8 DOI: https://doi.org/10.17925/OHR.2021.16.2.111
Multiple myeloma (MM) is a malignant clonal disorder of plasma cells in the bone marrow, and more than 32,000 new cases are expected in the USA each year.1 Many clinical advances, including novel drugs and continuous therapy with treatment sequencing, have improved survival statistics.2 Despite this, MM remains largely incurable and the relapsed/refractory population remains vulnerable […]
Pexidartinib and CSF1R Inhibitors as Treatment for Tenosynovial Giant Cell Tumors
Oncology & Hematology Review (US). 2020;16(2):119-23 DOI: https://doi.org/10.17925/OHR.2021.16.2.119
Tenosynovial giant cell tumor (TGCT)—previously referred to as giant cell tumor of the tendon sheath or pigmented villonodular synovitis (PVNS)—is a largely benign, rare, proliferative lesion arising from the synovial lining of joints, bursae, and tendon sheaths.1 This review serves to discuss the epidemiology, molecular biology, clinical behavior, and the current treatment modalities of TGCT that […]
Evolving Therapies for Urothelial Carcinoma—Novel Paradigms and Future Directions
Oncology & Hematology Review. 2020;16(2):82-9 DOI: https://doi.org/10.17925/OHR.2021.16.2.82
Urothelial carcinoma is the most common histologic type of bladder cancer in the USA and Europe, accounting for 90% of all bladder cancers. It is the sixth most common type of cancer diagnosed in the USA, and the 10th leading cause of cancer death, with an estimated 17,980 deaths predicted in 2020.1 Although the 5-year survival […]